These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 15611338

  • 21. The tuberous sclerosis complex (TSC) pathway and mechanism of size control.
    Potter CJ, Pedraza LG, Huang H, Xu T.
    Biochem Soc Trans; 2003 Jun; 31(Pt 3):584-6. PubMed ID: 12773160
    [Abstract] [Full Text] [Related]

  • 22. The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis.
    Strizheva GD, Carsillo T, Kruger WD, Sullivan EJ, Ryu JH, Henske EP.
    Am J Respir Crit Care Med; 2001 Jan; 163(1):253-8. PubMed ID: 11208653
    [Abstract] [Full Text] [Related]

  • 23. Regulation of TSC2 by 14-3-3 binding.
    Li Y, Inoki K, Yeung R, Guan KL.
    J Biol Chem; 2002 Nov 22; 277(47):44593-6. PubMed ID: 12364343
    [Abstract] [Full Text] [Related]

  • 24. Tumour suppressors hamartin and tuberin: intracellular signalling.
    Krymskaya VP.
    Cell Signal; 2003 Aug 22; 15(8):729-39. PubMed ID: 12781866
    [Abstract] [Full Text] [Related]

  • 25. Phosphorylation and binding partner analysis of the TSC1-TSC2 complex.
    Nellist M, Burgers PC, van den Ouweland AM, Halley DJ, Luider TM.
    Biochem Biophys Res Commun; 2005 Aug 05; 333(3):818-26. PubMed ID: 15963462
    [Abstract] [Full Text] [Related]

  • 26. Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells.
    Uhlmann EJ, Apicelli AJ, Baldwin RL, Burke SP, Bajenaru ML, Onda H, Kwiatkowski D, Gutmann DH.
    Oncogene; 2002 Jun 06; 21(25):4050-9. PubMed ID: 12037687
    [Abstract] [Full Text] [Related]

  • 27. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
    Finlay GA, Malhowski AJ, Liu Y, Fanburg BL, Kwiatkowski DJ, Toksoz D.
    Cancer Res; 2007 Oct 15; 67(20):9878-86. PubMed ID: 17942919
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.
    Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G.
    Mol Cell; 2003 Jun 15; 11(6):1457-66. PubMed ID: 12820960
    [Abstract] [Full Text] [Related]

  • 31. Tuberous sclerosis complex 2 loss-of-function mutation regulates reactive oxygen species production through Rac1 activation.
    Suzuki T, Das SK, Inoue H, Kazami M, Hino O, Kobayashi T, Yeung RS, Kobayashi K, Tadokoro T, Yamamoto Y.
    Biochem Biophys Res Commun; 2008 Mar 28; 368(1):132-7. PubMed ID: 18230340
    [Abstract] [Full Text] [Related]

  • 32. Tuberous sclerosis genes regulate cellular 14-3-3 protein levels.
    Hengstschläger M, Rosner M, Fountoulakis M, Lubec G.
    Biochem Biophys Res Commun; 2003 Dec 19; 312(3):676-83. PubMed ID: 14680818
    [Abstract] [Full Text] [Related]

  • 33. Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis.
    Niida Y, Lawrence-Smith N, Banwell A, Hammer E, Lewis J, Beauchamp RL, Sims K, Ramesh V, Ozelius L.
    Hum Mutat; 1999 Dec 19; 14(5):412-22. PubMed ID: 10533067
    [Abstract] [Full Text] [Related]

  • 34. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.
    Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D.
    Nat Cell Biol; 2003 Jun 19; 5(6):578-81. PubMed ID: 12771962
    [Abstract] [Full Text] [Related]

  • 35. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size.
    Potter CJ, Huang H, Xu T.
    Cell; 2001 May 04; 105(3):357-68. PubMed ID: 11348592
    [Abstract] [Full Text] [Related]

  • 36. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.
    Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG.
    Genes Dev; 2004 Dec 01; 18(23):2893-904. PubMed ID: 15545625
    [Abstract] [Full Text] [Related]

  • 37. Evidence for separable functions of tuberous sclerosis gene products in mammalian cell cycle regulation.
    Miloloza A, Kubista M, Rosner M, Hengstschläger M.
    J Neuropathol Exp Neurol; 2002 Feb 01; 61(2):154-63. PubMed ID: 11853018
    [Abstract] [Full Text] [Related]

  • 38. Aspects of tuberous sclerosis complex (TSC) protein function in the brain.
    Ramesh V.
    Biochem Soc Trans; 2003 Jun 01; 31(Pt 3):579-83. PubMed ID: 12773159
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Tuberous sclerosis complex: from Drosophila to human disease.
    Pan D, Dong J, Zhang Y, Gao X.
    Trends Cell Biol; 2004 Feb 01; 14(2):78-85. PubMed ID: 15102439
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.